1921
Volume 80, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

A key bench mark of successful therapeutic policy implementation, and thus effectiveness, is that the recommended drugs are available at the point of care. Two years after artemether-lumefathrine (AL) was introduced for the management of uncomplicated malaria in Kenya, we carried out a cross-sectional survey to investigate AL availability in government facilities in seven malaria-endemic districts. One of four of the surveyed facilities had none of the four AL weight-specific treatment packs in stock; three of four facilities were out of stock of at least one weight-specific AL pack, leading health workers to prescribe a range of inappropriate alternatives. The shortage was in large part caused by a delayed procurement process. National ministries of health and the international community must address the current shortcomings facing antimalarial drug supply to the public sector.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2009.80.737
2009-05-01
2017-11-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/80/5/0800737.html?itemId=/content/journals/10.4269/ajtmh.2009.80.737&mimeType=html&fmt=ahah

References

  1. Talisuna AO, Bloland P, D’Alessandro U, 2004. History, dynamics and public health importance of malaria parasite resistance. Clin Microbiol Rev 17 : 235–254.
  2. Attaran A, Barnes KI, Curtis C, D’Alessandro U, Fanello CI, Galinski MR, Kokwaro G, Looareesuwan S, Makanga M, Mutabingwa TK, Talisuna A, Trape JF, Watkins WM, 2004. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 363 : 237–240.
  3. World Health Organization, 2006. Guidelines for the Treatment of Malaria. Global Malaria Programme. Geneva: World Health Organization, WHO/HTM/MAL/ 2006: 1108.
  4. Bosman A, Mendis KN, 2007. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am J Trop Med Hyg 77 (Suppl 6): 193–197.
  5. Shretta R, Omumbo J, Rapuoda BA, Snow RW, 2000. Using evidence to change antimalarial drug policy in Kenya. Trop Med Int Health 5 : 755–764.
  6. Williams HA, Durrheim DN, Shretta R, 2004. The process of changing national malaria treatment policy: lessons from country level studies. Health Policy Plan 19 : 356–370.
  7. Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS, Snow RW, 2007. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J 6 : 72.
  8. Njogu J, Akhwale W, Hamer DH, Zurovac D, 2008. Health facility and health worker readiness to deliver new national treatment policy for malaria in Kenya. East Afr Med J 85 : 213–221.
  9. Zurovac D, Ndhlovu M, Sipilanyambe N, Chanda P, Hamer DH, Simon JL, Snow RW, 2007. Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study. Malar J 6 : 31.
  10. Zurovac D, Tibenderana JK, Nankabirwa J, Ssekitooleko J, Njogu JN, Rwakimari JB, Meek S, Talisuna A, Snow RW, 2008. Malaria case-management under artemether-lumefantrine treatment policy in Uganda. Malar J 7 : 181.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2009.80.737
Loading
/content/journals/10.4269/ajtmh.2009.80.737
Loading

Data & Media loading...

  • Received : 03 Dec 2008
  • Accepted : 16 Feb 2009

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error